GlassScriptPhysician profile
James Wilkins
NPI 1619465663
$2,030.61
in general payments reported to CMS, 2019-2025
30 companies · $902 in 2025
The $902 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11.80 · 2020: $15.29 · 2021: $14.72 · 2022: $202 · 2023: $309 · 2024: $576 · 2025: $902.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,787.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,787.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $209.35 | 2022-2025 | |
| Lilly USA, LLC | $208.49 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Abbott Laboratories | $207.44 | 2022-2025 | Freestyle Libre 3 |
| Abbvie INC. | $173.01 | 2022-2025 | Vraylar, Qulipta |
| Astrazeneca Pharmaceuticals LP | $122.24 | 2022-2025 | Breztri, Farxiga, Airsupra |
| Novo Nordisk INC | $106.31 | 2020-2025 | Wegovy, Ozempic, Rybelsus |
| Exact Sciences Corporation | $99.28 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Dexcom, INC. | $84.09 | 2024-2025 | Dexcom G6 Transmitter |
| Edwards Lifesciences Corporation | $77.93 | 2024-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Amgen INC. | $76.52 | 2021-2025 | Otezla, Repatha, Otezla |
| Corcept Therapeutics | $62.49 | 2024-2025 | Korlym |
| Stryker Corporation | $52.12 | 2025 | Clottriever Bold Catheter |
| Shield Therapeutics INC | $50.77 | 2024-2025 | |
| Daiichi Sankyo INC. | $47.36 | 2025 | Injectafer |
| Glaxosmithkline, LLC. | $42.90 | 2025 | Arexvy, Shingrix, Trelegy Ellipta |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $41.76 | 2025 | Voquezna |
| Merck Sharp & Dohme LLC | $39.13 | 2019-2025 | Gardasil 9, Capvaxive, Proquad |
| Biohaven Pharmaceutical Holding Company LTD. | $38.33 | 2022 | |
| Novartis Pharmaceuticals Corporation | $38.22 | 2022 | |
| Aimmune Therapeutics, INC. | $34.71 | 2025 | Zenpep |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $30.03 | 2025 | Xifaxan |
| Organon LLC | $27.85 | 2024-2025 | Nexplanon |
| Takeda Pharmaceuticals U.S.A., INC. | $27.26 | 2024 | Trintellix |
| Dynavax Technologies Corporation | $26.67 | 2025 | Heplisav-B |
| Sumitomo Pharma America, INC. | $23.78 | 2025 | Gemtesa |
| Inari Medical, INC. | $19.13 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Idorsia Pharmaceuticals US INC | $16.65 | 2023 | Quviviq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.38 | 2024 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $16.20 | 2025 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $14.21 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Wilkins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.